Eugenol is an important phenylpropanoid present in essential oil obtained from a number of plant species. It is responsible for the typical flavour and the aroma of these plants. Eugenol is known for its various pharmacological activities including anti‐diabetic activity. No systematic and scientific reports were available on its effect in diabetic nephropathy. Transforming growth factor β (TGF‐β) plays a central role in the progression of diabetic nephropathy. Down regulation of TGF‐β can prove a better approach for treatment of diabetic nephropathy. The present study was designed to evaluate the effect of eugenol in streptozotocin (STZ) induced type I diabetic nephropathy.
Diabetes was induced in male Sprague Dawley rats by administration of streptozotocin (55 mg kg‐1, i.p.). The effect of eugenol was studied at the dose of 5 and 10 mg kg‐1 day‐1. Treatment was done for 28 days. Assessment of plasma biochemical and urine parameters was done at the end of study. Oxidative stress markers in kidney were also evaluated. Changes in kidney histology were observed by Hematoxylin‐Eosin, Periodic Acid Schiff and Masson Trichrome staining. Expression of TGF‐β1 was determined by measuring the optical density in immunostained kidney sections.
Parameters associated with diabetic nephropathy were significantly shifted towards the normal level after treatment with eugenol. Eugenol also ameliorated the histological changes in the diabetic kidney. Expression of TGF‐β1 was increased significantly in the diabetic control group. However, eugenol treatment decreases this increased expression.
Results suggest that treatment with eugenol involved amelioration of diabetic nephropathy by decreasing TGF‐β1 expression. Copyright © 2016 John Wiley & Sons, Ltd.